公开(公告)号：US20150293120A1

公开(公告)日：2015-10-15

申请号：US14388533

申请日：2013-03-27

Applicant: PROTAGEN AG

Inventor： Angelika LÜKING ,  Peter SCHULZ-KNAPPE ,  Heike GÖHLER ,  Martin GAMER ,  Carmen THEEK ,  Daniel CHAMRAD ,  Anna TELAAR ,  Matthias VON DARL ,  Matthias SCHNEIDER ,  Jessica SCHWERMANN

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N33/6845 ,  G01N2570/00 ,  G01N2800/102 ,  G01N2800/60

Abstract: The present invention relates to a novel method for identifying marker sequences for rheumatoid arthritis, the novel marker sequences discovered with the aid of the method, and the diagnostic use thereof. The invention also relates to diagnostic devices containing such marker sequences for rheumatoid arthritis, in particular a protein biochip or beads (pellets), and use thereof.

Abstract translation: 本发明涉及用于鉴定类风湿性关节炎的标志物序列的新方法，借助该方法发现的新型标志物序列及其诊断用途。 本发明还涉及含有用于类风湿性关节炎，特别是蛋白质生物芯片或珠粒（颗粒）的标记序列的诊断装置及其用途。

公开(公告)号：US20190120834A1

公开(公告)日：2019-04-25

申请号：US16090620

申请日：2017-04-03

Applicant: PROTAGEN AG

Inventor： Angelika LÜKING ,  Petra BUDDE ,  Peter SCHULZ-KNAPPE ,  Dieter ZUCHT

IPC: G01N33/564

Abstract: The present invention relates to a novel method for identifying marker sequences for rheumatoid arthritis, the novel marker sequences discovered with the aid of the method, and the diagnostic use thereof. The invention also relates to diagnostic devices containing such marker sequences for rheumatoid arthritis, in particular a protein biochip or beads (pellets), and use thereof.

公开(公告)号：US20170199202A1

公开(公告)日：2017-07-13

申请号：US15324470

申请日：2015-07-04

Applicant: PROTAGEN AG

Inventor： Petra BUDDE ,  Peter SCHULZ-KNAPPE ,  Angelika LÜKING ,  Martin GAMER

IPC: G01N33/68 ,  C07K16/40 ,  C07K16/18 ,  G01N33/564 ,  C07K14/47

CPC classification number: G01N33/6893 ,  C07K14/47 ,  C07K16/18 ,  C07K16/40 ,  C07K2317/33 ,  C07K2317/34 ,  G01N33/564 ,  G01N2500/04 ,  G01N2800/24 ,  G01N2800/52

Abstract: The present invention relates to methods for identifying markers for systemic sclerosis (also scleroderma; SSc) and to the markers identified with the aid of this method, which can differentiate between SSc and other autoimmune diseases on the one hand and between different SSc subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control of SSc. The invention also relates to methods for screening and for validating active substances for use in SSc.

公开(公告)号：US20190128884A1

公开(公告)日：2019-05-02

申请号：US16310147

申请日：2017-06-15

Applicant: PROTAGEN AG

Inventor： Petra BUDDE ,  Angelika LÜKING ,  Peter SCHULZ-KNAPPE ,  Hans-Dieter ZUCHT

IPC: G01N33/564 ,  C07K16/24

Abstract: The present invention relates to a method for managing the therapy of patients and patient (sub)populations (responder/non-responder) suffering from rheumatoid arthritis (RA) and to the use of suitable marker sequences, in particular in the form of panels, diagnostic agents and test kits, and to their use in rheumatoid arthritis (RA) diagnosis, prognosis and therapy management, in particular for drug-based therapy.

公开(公告)号：US20170074875A1

公开(公告)日：2017-03-16

申请号：US15117508

申请日：2015-02-10

Applicant: PROTAGEN AG

Inventor： Angelika LÜKING ,  Peter SCHULZ-KNAPPE ,  Carmen THEEK ,  Petra BUDDE ,  Anna TELAAR

IPC: G01N33/564

Abstract: The present invention relates to methods for identifying markers for systemic lupus erythematosus (SLE) and to the markers identified with the aid of this method, which can differentiate between SLE and other autoimmune diseases on the one hand and between different SLE subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control in SLE. The invention also relates to methods for screening and validating active substances for application in SLE subgroups.

Abstract translation: 本发明涉及用于识别系统性红斑狼疮（SLE）的标志物的方法和借助于该方法鉴定的标记物，其一方面可以区分SLE和其他自身免疫性疾病，另一方面在不同的SLE亚组之间 。 本发明还涉及包括这些标记物的面板，诊断装置和测试试剂盒，以及其在SLE中的诊断，预后和治疗控制的用途和应用。 本发明还涉及用于筛选和验证在SLE亚组中应用的活性物质的方法。

公开(公告)号：US20150323529A1

公开(公告)日：2015-11-12

申请号：US14647513

申请日：2013-11-27

Applicant: PROTAGEN AG

Inventor： Heike GÖHLER ,  Marquart KLAUS ,  Andrew CHAN ,  Peter SCHULZ-KNAPPE ,  Carmen THEEK ,  Anna TELAAR ,  Martin GAMER

IPC: G01N33/564 ,  G01N21/64 ,  G06F19/24

CPC classification number: G01N33/564 ,  G01N21/6486 ,  G01N33/6896 ,  G01N2800/285 ,  G16B20/00 ,  G16B40/00

Abstract: The present invention relates to new markers for Neuromyelitis Optica (NMO), a method for identifying markers for NMO, the use of the markers identified by the method, diagnostic devices, panels of markers, assays, protein arrays comprising markers for NMO and a method for detecting NMO.

Abstract translation: 本发明涉及用于神经脊髓炎眼科（NMO）的新标记物，用于鉴定NMO标记物的方法，通过该方法鉴定的标记物的使用，诊断装置，标记物组，测定法，包含NMO标记的蛋白质阵列和方法 用于检测NMO。